Figures & data
Table 1 Baseline variables according to primary treatment for RVO-related CME
Figure 1 Three-month BCVA gain of the treatment-naïve CME eyes secondary to retinal vein occlusion.
Abbreviations: BCVA, best-corrected visual acuity; CME, cystoid macular edema; MAR, minimum angle of resolution; DEX, dexamethasone.
![Figure 1 Three-month BCVA gain of the treatment-naïve CME eyes secondary to retinal vein occlusion.](/cms/asset/c9bc0cac-4261-4d2e-8cc3-69d6e1f4e9ef/doph_a_144688_f0001_c.jpg)
Figure 2 Three-month CRT decrease of the treatment-naïve CME eyes secondary to retinal vein occlusion.
Abbreviations: CRT, central retinal thickness; CME, cystoid macular edema; DEX, dexamethasone.
![Figure 2 Three-month CRT decrease of the treatment-naïve CME eyes secondary to retinal vein occlusion.](/cms/asset/0070ce31-1c6f-4723-baba-6f3f3e77afb0/doph_a_144688_f0002_c.jpg)
Figure 3 Three-month IOP change of the treatment-naïve CME eyes secondary to retinal vein occlusion.
Abbreviations: IOP, intraocular pressure; CME, cystoid macular edema; DEX, dexamethasone.
![Figure 3 Three-month IOP change of the treatment-naïve CME eyes secondary to retinal vein occlusion.](/cms/asset/90103bf2-1599-40e3-bab2-f6c8d3276e81/doph_a_144688_f0003_c.jpg)